Polyclonal Antibody to Nuclear Receptor Coactivator 3 (NCOA3)
| Code | Size | Price |
|---|
| PAE798Hu01-20ul | 20ul | £87.00 |
Quantity:
| PAE798Hu01-100ul | 100ul | £162.00 |
Quantity:
| PAE798Hu01-200ul | 200ul | £218.00 |
Quantity:
| PAE798Hu01-1ml | 1ml | £499.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
RAC3; ACTR; AIB1; CAGH16; CTG26; SRC3; TNRC14; TNRC16; TRAM1; pCIP; Amplified In Breast 1; Steroid Receptor Coactivator-3 ; Thyroid Hormone Receptor Activator Molecule 1
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Nuclear Receptor Coactivator 3
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;1:240-900<br/>Immunohistochemistry: 5-20ug/mL;1:24-90<br/>Immunocytochemistry: 5-20ug/mL;1:24-90<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Nuclear Receptor Coactivator 3 (NCOA3) | RPE798Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||